Our Team
Lianli Li, Ph.D.
Founder and President
Lianli is the innovator and developer of Metronidazole Colon-Delivery technology. Her persistence brought this product from an idea to animal proof-of-concept, GMP manufacturing, FDA correspondence, and Phase 1 clinical study. 25 years of pharmaceutical industry experience from formulation scientist to VP of product development.
Erik Dubberke, M.D.
Medical Advisor
Erik is the medical and clinical collaborator of Metronidazole Colon-Delivery product for treating C. difficile infection. Strong supporter of metronidazole reformulation. Collaborated on Gateway’s NIH innovation grant. Specialized in C. difficile infection and fecal transplant. Professor at Washington University and Barnes Jewish Hospital.
Brian Cudney, MBA
Regulatory Affairs
Brian is the regulatory affairs partner with Lianli on this 505(b)(2) product, worked on Pre-IND meeting and IND submission. Brian has 20+ years of pharmaceutical CMC experience, with 10 years as Director of Regulatory Affairs at Cardinal Health.
Krishna Devarakonda, Ph.D.
Pharmacology & PK
Krishna is the animal and human pharmacokinetic studies partner on this project. A seasoned clinical pharmacologist and pharmacokinetics with 20 years of experience at Mallinckrodt Pharmaceuticals/Covidien on preclinical and clinical studies in growing roles to Director and VP.